Inspire Advisors LLC Has $798,000 Stock Position in IDEXX Laboratories, Inc. $IDXX

Inspire Advisors LLC grew its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 9.8% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,488 shares of the company’s stock after acquiring an additional 133 shares during the quarter. Inspire Advisors LLC’s holdings in IDEXX Laboratories were worth $798,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of the business. Pinnacle Wealth Planning Services Inc. bought a new stake in IDEXX Laboratories in the 2nd quarter valued at about $273,000. Dorsey & Whitney Trust CO LLC bought a new stake in shares of IDEXX Laboratories in the second quarter valued at approximately $241,000. Nomura Asset Management Co. Ltd. grew its position in IDEXX Laboratories by 2.8% during the second quarter. Nomura Asset Management Co. Ltd. now owns 60,561 shares of the company’s stock worth $32,481,000 after buying an additional 1,665 shares in the last quarter. Symphony Financial Ltd. Co. bought a new position in IDEXX Laboratories during the 2nd quarter worth $27,904,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH raised its holdings in IDEXX Laboratories by 15.3% in the 2nd quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 173,327 shares of the company’s stock valued at $92,962,000 after acquiring an additional 23,029 shares in the last quarter. 87.84% of the stock is owned by institutional investors.

IDEXX Laboratories Stock Performance

IDEXX Laboratories stock opened at $670.21 on Wednesday. The company has a quick ratio of 0.79, a current ratio of 1.11 and a debt-to-equity ratio of 0.31. The stock has a market cap of $53.52 billion, a PE ratio of 55.80, a P/E/G ratio of 4.06 and a beta of 1.62. IDEXX Laboratories, Inc. has a 12-month low of $356.14 and a 12-month high of $735.00. The business’s 50-day moving average price is $652.36 and its two-hundred day moving average price is $592.66.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Monday, November 3rd. The company reported $3.22 EPS for the quarter, topping analysts’ consensus estimates of $3.14 by $0.08. IDEXX Laboratories had a net margin of 24.41% and a return on equity of 64.42%. The firm had revenue of $1.11 billion during the quarter, compared to analysts’ expectations of $1.07 billion. During the same quarter in the prior year, the business earned $2.80 earnings per share. The business’s revenue for the quarter was up 13.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. As a group, analysts expect that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

Analyst Ratings Changes

IDXX has been the topic of several analyst reports. Wall Street Zen upgraded IDEXX Laboratories from a “buy” rating to a “strong-buy” rating in a research report on Sunday. BTIG Research increased their price objective on shares of IDEXX Laboratories from $785.00 to $830.00 and gave the stock a “buy” rating in a research note on Tuesday, November 4th. Piper Sandler reissued a “neutral” rating and issued a $700.00 target price (up from $510.00) on shares of IDEXX Laboratories in a report on Monday, August 11th. UBS Group boosted their target price on shares of IDEXX Laboratories from $710.00 to $750.00 and gave the company a “neutral” rating in a research report on Tuesday, November 4th. Finally, Stifel Nicolaus set a $775.00 price target on shares of IDEXX Laboratories in a report on Monday, November 3rd. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $730.50.

Insider Activity at IDEXX Laboratories

In other news, EVP Nimrata Hunt sold 9,425 shares of the stock in a transaction on Friday, November 7th. The stock was sold at an average price of $703.34, for a total value of $6,628,979.50. Following the completion of the transaction, the executive vice president directly owned 21,149 shares in the company, valued at approximately $14,874,937.66. This represents a 30.83% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director M Anne Szostak sold 2,187 shares of the firm’s stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $647.33, for a total value of $1,415,710.71. Following the sale, the director directly owned 262 shares in the company, valued at approximately $169,600.46. This trade represents a 89.30% decrease in their position. The SEC filing for this sale provides additional information. 0.98% of the stock is owned by corporate insiders.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.